ESC CONGRESS 2019

31 August - 04 September 2019, Paris - France

Session Details

Poster Session 2: Drug treatment for atrial fibrillation
Sun 01 Sep 08:30 - 12:30 European Society of Cardiology Poster Session, Abstract-based Programme Posters - Poster Area
Learning Objectives: Posters are on display from 08:30 – 12:30. Presenters will be by their poster during the coffee break from 10:05 and 10:55 for posters viewing time.

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
08:30P1898Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registriesGiulia MONTRASIO (Zurich, Switzerland)
08:30P1899Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION studyWalid AMARA (Le Raincy-Montfermeil, France)
08:30P1900Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation Miroslav MIHAJLOVIC (Belgrade, Serbia)
08:30P1901Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imagingMasahide HARADA (Toyoake, Japan)
08:30P1902Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples Orsolya HAJAS (Debrecen, Hungary)
08:30P1903Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trialsHarry CRIJNS (Maastricht, Netherlands (The))
08:30P1904Oral anticoagulation in patients undergoing elective cardioversion of atrial fibrillation. Real-life experience from FinlandSaga ITAINEN-STROMBERG (Helsinki, Finland)
08:30P1905Propofol suppresses atrial fibrillation in an experimental whole-heart modelJulian WOLFES (Munster, Germany)
08:30P1906Modified frailty as a novel factor to predict the effectiveness of electrical cardioversion of atrial fibrillation in the elderly populationAgnieszka MLYNARSKA (Myslowice, Poland)
08:30P1907Propensity score matched analysis of antazoline mesylate vs. amiodarone or propafenone for pharmacological cardioversion of short-duration atrial fibrillationMaciej WYBRANIEC (Katowice, Poland)